查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1791567

全球克隆与诱变市场

Cloning and Mutagenesis
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 178 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球克隆和诱变市场规模将达到 103 亿美元

全球克隆和诱变市场规模预计在2024年为34亿美元，预计到2030年将达到103亿美元，2024年至2030年的复合年增长率为20.0%。克隆试剂套件是本报告分析的细分市场之一，预计其复合年增长率为23.2%，到分析期结束时规模将达到51亿美元。诱变试剂套件细分市场在分析期间的复合年增长率预计为19.1%。

美国市场规模估计为 9.65 亿美元，中国市场预计复合年增长率为 18.7%

预计到2024年，美国克隆和诱变市场规模将达到9.065亿美元。作为世界第二大经济体，中国市场规模预计到2030年将达到16亿美元，在2024-2030年的分析期间内，复合年增长率为18.7%。其他值得关注的区域市场包括日本和加拿大，预计在分析期间内，这两个市场的复合年增长率分别为18.8%和16.9%。在欧洲，预计德国市场的复合年增长率约为14.3%。

全球克隆和诱变市场—主要趋势和驱动因素摘要

是什么推动了克隆和诱变需求的激增？

克隆和诱变已成为生物技术、製药和农业科学等各个领域的重要组成部分。对基因改造生物 (GMO) 和生物製药的日益增长的需求是该市场的主要驱动力。在医疗保健领域，基因治疗的进步推动了对克隆技术的需求，尤其是在再生医学和精准肿瘤学领域。此外，高通量诱变技术的发展大大加速了基因工程研究，使得能够创建功能增强的修饰蛋白质。癌症、糖尿病和遗传疾病等慢性疾病的增加加剧了分子生物学研究，进一步刺激了对克隆和诱变工具的投资。此外，操纵遗传物质用于药物发现和疫苗开发的能力正在增加市场的吸引力，尤其是随着 mRNA 技术的进步。製药公司正在利用这些技术生产更有效的治疗性蛋白质、抗体和基因编辑解决方案，从而在全球范围内广泛应用。

科技如何重塑复製和诱变的未来？

CRISPR-Cas9 和其他基因编辑技术的进步彻底改变了克隆和诱变的模式。次世代定序仪(NGS) 的引入使得精准基因修饰成为可能，并显着减少了传统上与这些技术相关的时间和成本限制。自动化和人工智慧主导的工作流程使实验室能够更有效率地进行高通量诱变实验，缩短了研究和产品开发的周转时间。此外，合成生物学与克隆和诱变技术的融合促进了新型生物合成途径的创建，从而拓展了这些技术的应用范围。定向进化方法的出现，利用诱变技术人工增强蛋白质功能，在酵素工程和工业生物技术领域获得了广泛关注。研究人员也致力于改进特异性诱变技术，以实现更精确的基因修饰，最大限度地减少脱靶效应，并提高实验结果的可靠性。

影响竞争格局的主要市场趋势有哪些？

市场竞争日益激烈，各公司都在大力投资研发以获得技术优势。推动市场扩张的关键趋势是提供克隆和诱变专业服务的合约研究组织（CRO）的兴起。这种转变在製药和生技公司中尤其明显，它们将研究外包以降低新药的成本和上市缩短时间。另一个新兴趋势是采用云端基础的生物资讯平台。这些平台使研究人员能够远端设计和分析诱变实验，促进协作并提高数据准确性。此外，开放获取基因资料库的激增使科学家能够利用庞大的基因资讯库进行更明智的克隆实验。随着相关人员寻求开发更个人化的治疗性介入，预计对合成生物学和精准医疗的资金增加将刺激进一步的技术创新。

推动市场扩张的成长要素有哪些？

克隆和诱变市场的成长受到多种因素的推动，包括对基因组研究的投入增加、在药物发现中的应用不断扩展以及合成生物学作用的不断扩大。疫情过后，製药业对诱变技术在抗体开发和疫苗研究中的依赖加剧，导致基因工程工具的采用率上升。此外，农业生物技术的进步，例如培育出抗病虫害和恶劣环境条件的基因改造作物，正在推动对克隆技术的需求。对更高效生产重组蛋白和生质燃料的需求也推动了工业生物技术中先进诱变技术的应用。此外，监管支持和政府对基因组编辑计划的资助进一步推动了市场扩张，使复製和诱变成为未来科技创新的重要支柱。

部分

产品类型（克隆试剂套件、诱变试剂套件、其他产品类型）、技术（拓扑 PCR 克隆技术、定点突变技术、平端克隆技术、无缝克隆技术、其他技术）、最终用户（生物製药/製药公司、CRO/CMO、学术/研究机构）

受访公司范例

  • Agilent Technologies, Inc.
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • Bolder BioTechnology, Inc.
  • Creative Biogene
  • Danaher Corporation
  • Genes2Me
  • Genewiz（Azenta Life Sciences）
  • Genomax Technologies Pte Ltd
  • GenScript
  • Integrated DNA Technologies（IDT）
  • Jena Bioscience GmbH
  • Merck KGaA
  • New England Biolabs
  • OriGene Technologies
  • Promega Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TransGen Biotech Co., Ltd.
  • Vazyme

人工智慧集成

全球产业分析师利用可操作的专家内容和人工智慧工具改变市场和竞争情报。

Global Industry Analysts 没有遵循典型的 LLM 或特定于行业的 SLM查询，而是建立了一个从世界各地的专家收集的内容库，其中包括视频录像、博客、搜寻引擎研究以及大量的公司、产品/服务和市场数据。

关税影响係数

全球产业分析师根据公司总部所在国家、製造地和进出口（成品和原始设备製造商）情况预测其竞争地位的变化。这种复杂而多面的市场动态预计将以多种方式影响竞争对手，包括销货成本(COGS) 上升、盈利下降、供应链重组以及其他微观和宏观市场动态。

目录

第一章调查方法

第二章执行摘要

  • 市场概览
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他地区

第四章 竞赛

简介目录
Product Code: MCP29999

Global Cloning and Mutagenesis Market to Reach US$10.3 Billion by 2030

The global market for Cloning and Mutagenesis estimated at US$3.4 Billion in the year 2024, is expected to reach US$10.3 Billion by 2030, growing at a CAGR of 20.0% over the analysis period 2024-2030. Cloning Kits, one of the segments analyzed in the report, is expected to record a 23.2% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Mutagenesis Kits segment is estimated at 19.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$906.5 Million While China is Forecast to Grow at 18.7% CAGR

The Cloning and Mutagenesis market in the U.S. is estimated at US$906.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 18.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 18.8% and 16.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 14.3% CAGR.

Global Cloning and Mutagenesis Market - Key Trends & Drivers Summarized

What Is Driving the Surging Demand for Cloning and Mutagenesis?

Cloning and mutagenesis have become integral components in various fields such as biotechnology, pharmaceuticals, and agricultural sciences. The increasing demand for genetically modified organisms (GMOs) and biopharmaceuticals is a crucial driver of this market. In the healthcare sector, gene therapy advancements have propelled the demand for cloning technologies, particularly for regenerative medicine and precision oncology. Furthermore, the development of high-throughput mutagenesis techniques has significantly accelerated research in genetic engineering, enabling the creation of modified proteins with enhanced functionalities. The rising prevalence of chronic diseases such as cancer, diabetes, and genetic disorders has intensified research efforts in molecular biology, further fueling investments in cloning and mutagenesis tools. Additionally, the ability to manipulate genetic material for drug discovery and vaccine development is enhancing the market’s attractiveness, particularly with the ongoing exploration of mRNA technology. Pharmaceutical companies are leveraging these technologies to produce more effective therapeutic proteins, antibodies, and gene-editing solutions, which are seeing increased adoption worldwide.

How Is Technology Reshaping the Future of Cloning and Mutagenesis?

Advancements in CRISPR-Cas9 and other gene-editing technologies have revolutionized the cloning and mutagenesis landscape. The introduction of next-generation sequencing (NGS) has enabled precise genetic modifications, drastically reducing time and cost constraints traditionally associated with these techniques. With automation and AI-driven workflows, laboratories are now able to execute high-throughput mutagenesis experiments with greater efficiency, ensuring faster turnaround times for research and product development. Moreover, the convergence of synthetic biology with cloning and mutagenesis is facilitating the creation of novel biosynthetic pathways, thereby expanding the application scope of these technologies. The emergence of directed evolution approaches, where mutagenesis is used to artificially enhance protein functions, has gained traction in enzyme engineering and industrial biotechnology. Researchers are also focusing on improving site-directed mutagenesis techniques to enable more precise genetic alterations, minimizing off-target effects and increasing reliability in experimental outcomes.

What Are the Key Market Trends That Are Shaping the Competitive Landscape?

The market landscape for cloning and mutagenesis is increasingly competitive, with companies investing heavily in research and development to gain a technological edge. A significant trend driving market expansion is the rise of contract research organizations (CROs) that provide specialized cloning and mutagenesis services. This shift is particularly notable in pharmaceutical and biotech firms, which are outsourcing research to reduce costs and accelerate time-to-market for new drugs. Another emerging trend is the adoption of cloud-based bioinformatics platforms that allow researchers to design and analyze mutagenesis experiments remotely, facilitating collaboration and improving data accuracy. Additionally, the proliferation of open-access genetic databases is enabling scientists to leverage vast genetic information repositories for more informed cloning experiments. The increasing funding for synthetic biology and precision medicine is expected to spur further innovations, as stakeholders seek to develop more personalized therapeutic interventions.

What Are the Growth Drivers Fueling Market Expansion?

The growth in the cloning and mutagenesis market is driven by several factors, including rising investments in genomic research, increasing applications in drug discovery, and the expanding role of synthetic biology. The pharmaceutical industry’s reliance on mutagenesis for antibody development and vaccine research has intensified post-pandemic, leading to higher adoption rates of genetic engineering tools. Moreover, advancements in agriculture biotechnology, such as the creation of genetically modified crops resistant to pests and harsh environmental conditions, are propelling the demand for cloning technologies. The need for more efficient production of recombinant proteins and biofuels has also driven the adoption of advanced mutagenesis techniques in industrial biotechnology. Additionally, regulatory support and government funding for genome-editing projects are further boosting market expansion, making cloning and mutagenesis an essential pillar of future scientific innovations.

SCOPE OF STUDY:

The report analyzes the Cloning and Mutagenesis market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Cloning Kits, Mutagenesis Kits, Other Product Types); Technology (Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology, Other Technologies); End-Use (Biopharmaceutical and Pharmaceutical Companies End-Use, CROs and CMOs End-Use, Academic and Research Institutes End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 42 Featured) -

  • Agilent Technologies, Inc.
  • Assay Genie
  • Bio-Rad Laboratories, Inc.
  • Bolder BioTechnology, Inc.
  • Creative Biogene
  • Danaher Corporation
  • Genes2Me
  • Genewiz (Azenta Life Sciences)
  • Genomax Technologies Pte Ltd
  • GenScript
  • Integrated DNA Technologies (IDT)
  • Jena Bioscience GmbH
  • Merck KGaA
  • New England Biolabs
  • OriGene Technologies
  • Promega Corporation
  • Takara Bio Inc.
  • Thermo Fisher Scientific, Inc.
  • TransGen Biotech Co., Ltd.
  • Vazyme

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Cloning and Mutagenesis - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Applications of Functional Genomics and Protein Engineering Propel Growth of Cloning and Mutagenesis Tools
    • Expanding Biopharmaceutical R&D Activity Drives Demand for High-Fidelity Gene Cloning and Mutagenesis Technologies
    • Advancements in Site-Directed Mutagenesis Enhance Efficiency of Precision Genetic Modifications
    • Growing Use of Recombinant DNA Technologies in Synthetic Biology Expands Adoption of Cloning Techniques
    • Increased Demand for Custom Gene Synthesis and Expression Cloning Generates Market Opportunities
    • Rapid Progress in CRISPR and Genome Editing Research Spurs Adoption of Mutagenesis Protocols
    • Integration of Automation and High-Throughput Screening Enhances Workflow Efficiency in Cloning and Mutagenesis Labs
    • Expansion of Academic and Research Institutions Globally Strengthens Demand for Gene Manipulation Kits
    • Rising Focus on Protein Structure-Function Studies Propels Market for Directed Evolution and Mutagenesis
    • Growing Biotech Startup Activity Accelerates Commercial Use of Cloning Vectors and Mutation Libraries
    • Increased Application of Mutagenesis in Vaccine Development Drives Market Growth
    • Adoption of Mutagenesis Techniques for Enzyme Optimization and Industrial Biocatalysts Expands Use Cases
    • Rising Investments in Agricultural Biotechnology Fuel Demand for Plant Gene Cloning and Trait Improvement
    • Growing Trend Toward Personalized Medicine Supports Custom Gene Editing and Cloning Solutions
    • Availability of Cloud-Based Bioinformatics Tools Enhances Adoption of Cloning and Mutagenesis Protocols
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Cloning and Mutagenesis Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cloning Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Cloning Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Mutagenesis Kits by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Mutagenesis Kits by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Other Product Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Other Product Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for CROs & CMOs End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for CROs & CMOs End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Biopharmaceutical & Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Topo PCR Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Topo PCR Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Site-directed Mutagenesis Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Site-directed Mutagenesis Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Blunt End Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Blunt End Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Seamless Cloning Technology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Seamless Cloning Technology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Other Technologies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Other Technologies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 28: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: USA 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 30: USA Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: USA 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 34: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Canada 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 36: Canada Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Canada 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • JAPAN
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 40: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Japan 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 42: Japan Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Japan 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • CHINA
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 46: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: China 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 48: China Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: China 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • EUROPE
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for Cloning and Mutagenesis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 54: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • FRANCE
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 58: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 60: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: France 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • GERMANY
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 64: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 66: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Germany 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • ITALY
    • TABLE 70: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 72: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Italy 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • UNITED KINGDOM
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 76: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 78: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: UK 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 84: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Cloning and Mutagenesis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 90: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Product Type - Cloning Kits, Mutagenesis Kits and Other Product Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Product Type - Percentage Breakdown of Value Sales for Cloning Kits, Mutagenesis Kits and Other Product Types for the Years 2025 & 2030
    • TABLE 96: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by End-Use - CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Rest of World 6-Year Perspective for Cloning and Mutagenesis by End-Use - Percentage Breakdown of Value Sales for CROs & CMOs End-Use, Academic & Research Institutes End-Use and Biopharmaceutical & Pharmaceutical Companies End-Use for the Years 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cloning and Mutagenesis by Technology - Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World 6-Year Perspective for Cloning and Mutagenesis by Technology - Percentage Breakdown of Value Sales for Topo PCR Cloning Technology, Site-directed Mutagenesis Technology, Blunt End Cloning Technology, Seamless Cloning Technology and Other Technologies for the Years 2025 & 2030

IV. COMPETITION